Celyad Oncology (CLYYF) 6-K 7 Aug 20 2020 Q2 Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2020
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Registrant Name	Celyad Oncology SA
Entity Central Index Key	0001637890
Current Fiscal Year End Date	--12-31

Interim Consolidated Statement

Interim Consolidated Statement of Financial Position - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Statement of financial position [abstract]
NON-CURRENT ASSETS	€ 46,321	€ 47,000
Goodwill and Intangible assets	36,106	36,199
Property, plant and equipment	4,231	5,061
Non-current Trade and Other receivables	2,375	2,432
Non-current Grant receivables	3,378	3,051
Other non-current assets	231	257
CURRENT ASSETS	29,439	42,836
Trade and Other Receivables	972	558
Current Grant receivables	841	1,686
Other current assets	934	1,253
Short-term investments		0
Cash and cash equivalents	26,692	39,338
TOTAL ASSETS	75,760	89,836
EQUITY	30,318	45,619
Share capital	48,513	48,513
Share premium	43,349	43,349
Other reserves	29,477	28,181
Accumulated deficit	(91,021)	(74,424)
NON-CURRENT LIABILITIES	34,644	32,295
Bank loans		37
Lease liabilities	2,509	2,967
Recoverable Cash advances (RCA's)	4,538	4,139
Contingent consideration payable and other financial liabilities	27,199	24,754
Post-employment benefits	398	398
CURRENT LIABILITIES	10,798	11,922
Bank loans	91	192
Lease liabilities	1,104	1,167
Recoverable Cash advances (RCA's)	613	346
Trade payables	5,782	6,969
Other current liabilities	3,208	3,248
TOTAL EQUITY AND LIABILITIES	€ 75,760	€ 89,836

Interim Consolidated Statemen_2

Interim Consolidated Statement of Comprehensive Income - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Profit or loss [abstract]
Revenue	€ 5
Cost of sales
Gross profit	5
Research and Development expenses	(11,141)	(12,706)
General & Administrative expenses	(4,789)	(4,506)
Other income	2,026	1,311
Other expenses	(2,656)	(49)
Operating Loss	(16,555)	(15,950)
Financial income	112	244
Financial expenses	(154)	(259)
Loss before taxes	(16,597)	(15,965)
Income taxes	0
Loss for the period	€ (16,597)	€ (15,965)
Basic and diluted loss per share (in €)	€ (119)	€ (134)
Other comprehensive income/(loss)
Items that will not be reclassified to profit and loss
Remeasurements of post-employment benefit obligations, net of tax
Items that may be subsequently reclassified to profit or loss	7	€ 3
Currency translation differences	7	3
Other comprehensive income / (loss) for the period, net of tax	7	3
Total comprehensive loss for the period	(16,590)	(15,962)
Total comprehensive loss for the period attributable to Equity Holders	€ (16,590)	€ (15,962)

Interim Consolidated Statemen_3

Interim Consolidated Statement of Changes in Equity - EUR (€) € in Thousands	Total	Share capital [member]	Share premium [member]	Other reserves [member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2018	€ 55,590	€ 41,553	€ 206,149	€ 25,667	€ (217,778)
Share-based payments	1,291			1,291
Total transactions with owners, recognized directly in equity	1,291			1,291
Loss for the period	(15,965)				(15,965)
Reduction of share premium by absorption of losses			(172,287)		172,287
Currency Translation differences	3			3
Total comprehensive loss for the period	(15,962)		(172,287)	3	156,322
Ending balance at Jun. 30, 2019	40,919	41,553	33,862	26,960	(61,456)
Capital increase	18,169	6,960	11,209
Transaction costs associated with capital increases	(1,721)		(1,721)
Share-based payments	1,484			1,484
Total transactions with owners, recognized directly in equity	17,932	6,960	9,488	1,484
Loss for the period	(12,667)				(12,667)
Currency Translation differences	(264)			(264)
Remeasurements of defined benefit obligation	(301)				(301)
Total comprehensive loss for the period	(13,232)			(264)	(12,968)
Ending balance at Dec. 31, 2019	45,619	48,513	43,349	28,181	(74,424)
Exercise of warrants	0
Share-based payments	1,289			1,289
Total transactions with owners, recognized directly in equity	1,289			1,289
Loss for the period	(16,597)				(16,597)
Currency Translation differences	7			7
Remeasurements of defined benefit obligation
Total comprehensive loss for the period	(16,590)			7	(16,597)
Ending balance at Jun. 30, 2020	€ 30,318	€ 48,513	€ 43,349	€ 29,477	€ (91,021)

Interim Consolidated Statements

Interim Consolidated Statements of Cash Flows - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flow from operating activities
Loss for the period	€ (16,597)	€ (15,965)
Non-cash adjustments
Intangibles - Amortization and impairment	95	81
Property, plant & equipment - Depreciation	792	802
Change in fair value of contingent consideration payable and other financial liabilities	2,445	(407)
Remeasurement of Recoverable Cash Advances (RCA's)	106	13
Grant income (RCA's and others)	(1,638)	(517)
Loss on disposal of property, plant and equipment		0
Share-based payment expense	1,289	1,291
Post-employment benefits		0
Change in working capital
Trade receivables, other (non-)current receivables	(246)	(216)
Trade payables, other (non-)current liabilities	(878)	(1,145)
Net cash used in operations	(14,633)	(16,063)
Cash Flow from investing activities
Acquisition of Property, Plant & Equipment	(72)	(215)
Acquisitions of Intangible assets	(1)	(4)
Disposals of Property, Plant & Equipment		0
Proceeds from net investment in lease	124	112
Contingent liability pay-out		0
Acquisition of short-term investments		0
Proceeds from short-term investments		9,197
Net cash from/(used in) investing activities	50	9,090
Cash Flow from financing activities
Proceeds from bank borrowings		0
Repayments of bank borrowings	(138)	(142)
Proceeds from leases		0
Repayments of leases	(628)	(591)
Proceeds from issuance of shares and exercise of warrants		0
Proceeds from RCA's & other grants	2,695	1,086
Repayment of RCA's & other grants		(256)
Net cash from/(used in) financing activities	1,929	97
Net cash and cash equivalents at beginning of the period	39,338	40,542
Change in Cash and cash equivalents	(12,653)	(6,876)
Effects of exchange rate changes on cash and cash equivalents	7	2
Net cash and cash equivalents at the end of the period	€ 26,692	€ 33,668

General information and Stateme

General information and Statement of Compliance	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
General Information	2.5.1 General information Celyad Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. Celyad Oncology SA was funded in 2007 as a limited liability company (Société Anonyme) governed by Belgian law with its registered office at Axis Parc, Rue Edouard Belin 2, B-1435 The Company has three fully owned subsidiaries (together, the Group) located in Belgium (Biological Manufacturing Services SA) and in the United States (Celyad Inc. and Corquest Medical, Inc.). The interim condensed consolidated financial statements have been approved for issuance by the Company’s Board of Directors on August 6, 2020, but have not been audited. The interim report is available to the public free of charge and upon request to the above-mentioned address or via the Company’s website ( https://celyad.com/investors/regulated-information/

Basis of preparation and signif

Basis of preparation and significant accounting policies	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Basis of preparation and significant accounting policies	2.5.2 Basis of preparation and significant accounting policies The interim condensed consolidated financial statements of the Group for the six months ended June 30, 2020 (the “interim period”) include Celyad Oncology SA and its subsidiaries. The significant accounting policies used for preparing the interim condensed consolidated financial statements are explained below. 2.5.2.1 Basis of preparation of half year report The interim condensed consolidated financial statements have been prepared in accordance with the IFRS as issued by the IASB and in accordance with the IFRS as issued by the IASB and as adopted for use in the European Union, and with IAS 34, Interim Financial Reporting. They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the annual financial statements for the year ended December 31, 2019. The preparation of the Company’s financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the end of the interim period. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods. The principal risks during the interim period have not materially changed from those mentioned in the 2019 Annual Report and subsequent reports and filings made with the SEC, each of which are available on the Company’s website ( http://www.celyad.com/investors/regulated-information The COVID-19 All statements and information relate to the interim period unless otherwise stated. The interim condensed consolidated financial statements are presented in thousands of Euros and all values are rounded to the nearest thousand (€’000) except when otherwise indicated. Amounts have been rounded off to the nearest thousand and in certain cases, this may result in minor discrepancies in the totals and sub-totals 2.5.2.2 New standards, interpretations and amendments The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period. None of the new standards, interpretations and amendments, which are effective for periods beginning after January 1, 2020 which have been issued by the IASB and the IFRIC but are not yet effective as per June 30, 2020 and/or not yet adopted by the European Union as per June 30, 2020, are expected to have a material effect on the Group’s future financial statements. 2.5.2.3 Critical accounting estimates and judgments The preparation of interim financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that may significantly affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the end of the reporting period. Refer to the disclosure note 5.4 from the Group’s 2019 year-end

Segment reporting

Segment reporting	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Segment reporting	2.5.3 Segment reporting The chief operating decision-maker (CODM), who is responsible for making strategic decisions, allocating resources and assessing performance of the Group, has been identified as the Board of Directors. Since the acquisition of the oncological platform in 2015, the management and the CODM have determined that there are two operating segments, being: - the immuno-oncology segment regrouping all assets developed based on the CAR-T - the cardiology segment, regrouping the Cardiopoiesis platform and C-Cath ez Corporate segment includes costs for general and administration functions not allocated to the other business segments. Although the Group is currently active in Europe and in the United States, no geographical financial information is currently available given the fact that the core operations are currently still in a study phase. No disaggregated information on product level or geographical level or any other level currently exists and hence is also not considered by the Board of Directors for assessing performance or allocating resources. The CODM is not reviewing assets by segments, hence no segment information per asset is disclosed. As of June 30, 2020, the main Group’s non-current Since mid of 2016, the Group is fully focused on the development of its immuno-oncology platform. Therefore, as of June 30, 2020, most of the R&D expenses were incurred in the immuno-oncology segment, in line with prior year. For the Six-month € ‘000 Cardiology Immuno-oncology Corporate Group Total Revenue recognized at a point in time — — — — Revenue recognized over time — — — — Total Revenue — — — — Cost of Sales — — — — Gross Profit — — — — Research & Development expenses (94 ) (12 612 ) — (12 706 ) General & Administrative expenses — — (4 506 ) (4 506 ) Net Other income/(loss) 134 927 201 1 262 Operating Profit/(Loss) 40 (11 685 ) (4 305 ) (15 950 ) Net financial income/(loss) 93 (93 ) (15 ) (15 ) Profit/(Loss) before taxes 133 (11 778 ) (4 320 ) (15 965 ) Income Taxes — — — — Profit/(Loss) for the year 2019 133 (11 778 ) (4 320 ) (15 965 ) For the Six-month € ‘000 Cardiology Immuno-oncology Corporate Group Total Revenue recognized at a point in time 5 — — 5 Revenue recognized over time — — — — Total Revenue 5 — — 5 Cost of Sales — — — — Gross Profit 5 — — 5 Research & Development expenses (72 ) (11 069 ) — (11 141 ) General & Administrative expenses — — (4 789 ) (4 789 ) Net Other income/(loss) 10 (840 ) 200 (630 ) Operating Profit/(Loss) (57 ) (11 908 ) (4 589 ) (16 555 ) Net financial income/(loss) — (87 ) 45 (42 ) Profit/(Loss) before taxes (57 ) (11 995 ) (4 545 ) (16 597 ) Income Taxes — — (0 ) (0 ) Profit/(Loss) for the year 2020 (57 ) (11 995 ) (4 545 ) (16 597 )

Off-Balance Sheet Commitments

Off-Balance Sheet Commitments	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Off-Balance Sheet Commitments	2.5.4 Off-Balance Sheet Commitments As of the date of this report, the Group has no off-balance year-end

Capital Expenditures

Capital Expenditures	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Capital Expenditures	2.5.5 Capital Expenditures In accordance with IAS 38, the Group does not capitalize its research and development expenses until the Group receives marketing authorization for the applicable product candidate. Research and development expenditures incurred during the interim period were accounted for as operating expenses.

Results of Operations

Results of Operations	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Results of operations	2.5.6 Results of operations Revenue For the Six-month period ended June 30, (€‘000) 2020 2019 Out-licensing — — Other revenue 5 — Total Revenue 5 — The Group did not enter into license agreements for the Six-month The Group does not expect to generate material revenue unless and until the Group receives regulatory approval for one of its drug product candidates. Research and development expenses The following table is a summary of manufacturing expenses, clinical, quality and regulatory expenses and other research and development expenses, which are aggregated and presented as research and development expenses in the Group’s consolidated financial statements. For the Six-month period ended June 30, (€‘000) 2020 2019 Employee expenses 4 528 4 179 Travel & Living 107 198 Clinical study costs 2 720 2 786 Preclinical study costs 866 1 729 Process development and scale-up 803 1 504 Consulting fees 191 574 IP filing and maintenance fees 141 135 Share-based payments 398 515 Depreciation 727 719 Rent and utilities 415 366 Others 245 2 Total R&D expenses 11 141 12 706 Research and development expenses totaled €11.1 million for the six-month CYAD-01 CYAD-02 CYAD-101, CYAD-211 CYAD-103 CYAD-200 General and administrative expenses For the Six-month period ended June 30, (€‘000) 2020 2019 Employee expenses 1 733 1 951 Consulting fees 1 025 865 Share-based payments 892 776 Communication & Marketing 289 339 Rent 40 18 Insurances 476 213 Travel & living 77 166 Depreciation 168 177 Others 89 1 Total General and administrative expenses 4 789 4 506 General and administrative expenses increased by €0.3 million over the six-month six-month (non-cash Other income and Other expenses For the Six-month period ended June 30, (€‘000) 2020 2019 Remeasurement of contingent consideration 2 445 — Clinical Development milestone payment 105 — Remeasurement of RCA’s 105 13 Fair value adjustment on securities — — Others 0 36 Total Other Expenses 2 656 49 Grant income (RCA’s) 615 517 Grant income (Other) 1 023 — Remeasurement of RCA’s — — Fair value adjustment on securities — 182 Remeasurement of contingent consideration — 407 R&D tax credit 371 205 Others 16 — Total Other Income 2 026 1 311 Other income Other income is mainly related to regional government recoverable cash advances (RCA’s) and other grants received in 2020: - Grant income (RCA’s): as of June 30, 2020, the Walloon Region proceeded with a further €1.4 million settlement in the form of recoverable cash advances (RCAs) for contracts, numbered 8087, 8088 and 1910028. According to IFRS standards, the Company has recognized grant income for the period amounting to €0.6 million and a liability component of €0.8 million is accounted for as a financial liability (see disclosure note 2.5.12). - Grant income (Others): additional grant income has been recognized in 2020 on grants received from the Federal Belgian Institute for Health Insurance Inami (€0.2 million) and from the regional government (contract numbered 8066 for €0.8 million), not referring to RCAs and not subject to reimbursement. With respect to R&D tax credit, the current year income is predicated on a R&D tax credit recorded (€0.4 million). Other expenses Other expenses increase compared to prior year refers to the following drivers: ◾ The fair value adjustment related to the contingent consideration and other financial liabilities incurs a €2.4 million expense at June 30, 2020 compared to a €0.4 million in income for the comparative period. The difference was mainly driven by discount rate (WACC) update and time accretion (which reflects the development of the Group’s product candidates using CAR T technology and their progress towards market approval in both autologous and allogeneic programs, as well as the update of its underlying business plans and revenue forecast), both partly compensated by USD foreign exchange rate update as of June 30, 2020; ◾ Clinical development milestone was paid for an amount of €0.1 million related to the first patient injection in the CYAD-02 ◾ Remeasurement expense of RCA’s is not significant for the current period, given the fact that the Group’s management has maintained in line with prior period the timeline to commercialization and sales forecast for its CAR-T Operating loss As a result of the foregoing, the Group’s operating loss, totaled €16.6 million at June 30, 2020, an increase of €0.6 million as compared to the six-month Financial income and financial expenses The financial income decrease of €0.2 million is primarly driven by interest income on short term deposits through the Group decision to reduce the amounts invested in short-term deposits over 2019 given the level of market interest rates of corporate deposits of short-term maturities. Financial expense refers mainly to interest expense on lease agreements for an amount of €0.1 million at June 30, 2020. Loss for the period As a result, the Group’s loss for the six-month Loss per share The loss per share is calculated by dividing loss for the period by the weighted average number of ordinary shares outstanding during the period. As the Group is incurring net losses, outstanding warrants have an anti-dilutive effect. As such, there is no difference between the basic and the diluted earnings per share. In case the warrants would be included in the calculation of the loss per share, this would decrease the loss per share. For the Six-month period ended June 30, (€‘000) 2020 2019 Loss for the period attributable to Equity Holders (16 597 ) (15 965 ) Weighted average number of shares outstanding 13 942 344 11 942 344 Earnings per share (non-fully (1,19 ) (1,34 ) Outstanding warrants 1 594 156 1 292 380

Liquidity and Capital Resources

Liquidity and Capital Resources	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Liquidity and capital resources	2.5.7 Liquidity and capital resources The Group’s liquidity requirements primarily relate to the funding of research & development, general & administrative expenses and working capital requirements. The Group monitors its risk exposure to a shortage of funds using a monthly liquidity planning tool. Its objective is to maintain a balance between continuity of funding and flexibility through the use of bank deposits and finance leases. Through June 30, 2020, the Group funded its operations through several private and public investments totaling, since inception, approximately €297 million (respectively, approximately €67 million and €230 million). The Group also received non-dilutive Recoverable Cash Advances (RCA’s), recorded as financial liabilities for an amount of €5.2 million at June 30, 2020, correspond to the risk-adjusted present value of expected future repayments of amounts granted by the Walloon Region, to support specific development programs related to C-Cath ez CYAD-02 CYAD-03/103. Additional grants have been received from the Federal Belgian Institute for Health Insurance Inami (€0.4 million fully cash settled in 2019) and from the regional government (contract numbered 8066 for €2.4 million, out of which €1.9 million has been effectively paid out as of June 30, 2020). Those grants are not subject to future reimbursement (as it is the case for the RCA’s described above). The Group is also exposed to contingent liabilities as a result of the license agreement executed with Celdara Medical, LLC. The risk adjusted present value of expected cash outflows (mainly towards Celdara) is recorded as a financial liability for an amount of €27.2 million at June 30, 2020. The following table sets forth the Group’s condensed interim consolidated cash flows information for the six-month For the Six-month period ended June 30, (€‘000) 2020 2019 Net cash used in operations (14 633 ) (16 063 ) Net cash (used in)/from investing activities 50 9 090 Net cash (used in)/from financing activities 1 929 97 Effects of exchange rate changes 7 2 Change in Cash and cash equivalents (12 646 ) (6 874 ) Change in Short-term investments — (9 197 ) Net cash burned over the period (12 646 ) (16 071 ) The cash outflow resulting from operating activities amounted to €14.6 million for the six months ended June 30, as compared to €16.1 million for the six months ended June 30, 2019. The €1.4 million decrease was primarily driven by lower preclinical and process development expenses and decreased clinical costs associated with the autologous r/r AML and MDS franchise. Cash flow from investing activities represented a net cash inflow of €0.1 million for the six months ended June 30, 2020, decrease of €9.0 million in comparison with prior year’s period, which largely driven by proceeds from short-term investments. Cash flow from financing activities in the first half of 2020 represented a net cash inflow of €1.9 million compared to a cash flow of €0.1 million for prior year’s period. The increase of €1.8 million is mainly related to higher proceeds received from Walloon Region for €2.7 million (€1.4 million related to RCA’s and €1.3 million related to other grants) compared to proceeds for €1.1 million during the same period 2019.

Goodwill and Intangible assets

Goodwill and Intangible assets	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Goodwill and Intangible assets	2.5.8 Goodwill and Intangible assets As of June 30, As of December 31, (€‘000) 2020 2019 OnCyte IPRD 33 676 33 676 C-Cath 573 607 Goodwill 883 883 Patents & Licenses 911 964 Other intangible assets 62 69 Total Goodwill and Intangible assets 36 106 36 199 The variance on the total intangible assets as of June 30, 2020 resulted primarily from the regular amortization of C-Cath ez

Trade and Other receivables

Trade and Other receivables	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Trade and Other receivables	2.5.9 Trade and Other receivables As of June 30, As of December 31, (€‘000) 2020 2019 R&D Tax credit receivable 3 378 3 051 Total Non-current Grant receivables 3 378 3 051 Deposits 231 257 Total Other non-current 231 257 As of June 30, As of December 31, (€‘000) 2020 2019 Non-current 2 032 1 955 Net investment in Lease 343 477 Total Non-current 2 375 2 432 As of June 30, As of December 31, (€‘000) 2020 2019 Trade receivables 451 156 Advance deposits 260 149 Net Investment in Lease 261 253 Other receivables — — Total Trade and Other receivables 972 558 Current Grant receivables (RCAs) 272 693 Current Grant receivables (Others) 569 993 Total Current Grant receivables 841 1 686 Prepaid expenses 364 646 VAT receivable 430 356 Income and other tax receivables 140 251 Total Other current assets 934 1 253 Total Trade receivables, advances and other current assets 2 747 3 497 The trade and other receivables increased by €0.4 million, mainly explained by a trade receivable on the sales of equipment under a sale and leaseback agreement. The decrease on current grant receivables for €0.8 million is primarily driven by cash proceeds received from the Walloon Region during the first half of 2020. The decrease on other current assets as of June 30, 2020 compared to first half of 2019 for €0.3 million is primarily driven by the decrease on prepaid expenses on insurances.

Short-term investments and Cash

Short-term investments and Cash and Cash equivalents	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Short-term investments and Cash and Cash equivalents	2.5.10 Short-term investments and Cash and Cash equivalents As of June 30, As of December 31, (€‘000) 2020 2019 Short-term investments — — Cash and cash equivalents 26 692 39 338 Total Short-term investments and Cash and Cash equivalents 26 692 39 338 The Group’s treasury position 1 year-end Given the level of market interest rates for corporate deposits of short-term maturities, the Group has reduced the amounts invested in short-term deposits over the years 2019. 1 ‘Treasury position’ is an alternative performance measure determined by adding Short-term investments and Cash and cash equivalents from the statement of financial position prepared in accordance with IFRS.

Capital and share premium

Capital and share premium	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Capital and share premium	2.5.11 Capital and share premium As of June 30, As of December 31, (€‘000) 2020 2019 Capital 48 513 48 513 Share premium 43 349 43 349 # Outstanding shares 13 942 344 13 942 344 As of June 30, 2020, share capital amounted to €48.5 million represented by 13,942,344 ordinary shares with no nominal value, in line with prior year-end. non-employees There were no capital increases over the course of the first half of 2020. As of June 30, 2020, all shares issued have been fully paid.

Recoverable Cash Advances

Recoverable Cash Advances	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Recoverable Cash Advances	2.5.12 Recoverable Cash Advances As of June 30, As of December 31, (€‘000) 2020 2019 Non-current 4 538 4 139 Current portion 613 346 Total Recoverable Cash Advances 5 151 4 484 The €0.7 million net increase in the Recoverable Cash Advances (RCA) total balance mainly refers to €0.8 million liability component of the cash settlement (€1.4 million) made by the Walloon Region in first half 2020—See disclosure note 2.5.6. Underlying R&D is ongoing and no exploitation decisions are expected before mid-2021

Trade Payables and Other Curren

Trade Payables and Other Current Liabilities	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Trade Payables and Other Current Liabilities	2.5.13 Trade payables and other current liabilities As of June 30, As of December 31, (€‘000) 2020 2019 Total trade payables 5 782 6 969 Other current liabilities Social security 165 482 Payroll accruals and taxes 1 480 1 750 Other current liabilities 1 563 1 016 Total other current liabilities 3 208 3 248 Total Trade payables and other current liabilities 8 989 10 217 Trade payables The decrease in trade payables for €1.2 million mainly relates to decrease in payables related to process development and clinical operations expenses. Other current liabilities As of June 30, 2020, the decrease on social security, payroll accruals and taxes by €0.6 million compared to December 31, 2019 related to timing differences on these accruals. Other current liabilities increase of €0.5 million is mainly explained by the establishment of an accrual to cover for a €1.0 million reimbursement of R&D tax credit related to an asessment resulting from an audit of fiscal years 2013 and 2014. While management plans to appeal the assessment, currently management has determined that it is probable that reimbursement will be required. This accrual is mainly offset by the recognition of deferred revenue related to the Federal Belgian Institute for Health Insurance Inami (€0.2 million).

Financial Instruments Fair Valu

Financial Instruments Fair Value Disclosures	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Financial instruments fair value disclosures	2.5.14 Financial instruments fair value disclosures 2.5.14.1 Financial instruments not reported at fair value on balance sheet The carrying and fair values of financial instruments that are not reported at fair value in the interim financial statements were as follows for the current and comparative periods: As of June 30, As of December 31, (€‘000) 2020 2019 Financial Assets (‘Amortized cost’ category) within: Non-current 2 375 2 432 Other non-current 231 257 Trade receivables and other current assets 972 558 Short-term investments — — Cash and cash equivalents 26 692 39 338 Total 30 272 42 586 As of June 30, As of December 31, (€‘000) 2020 2019 Financial Liabilities (‘Financial liabilities at amortized cost’ category) within: Bank loans 91 229 RCA’s liability 5 151 4 484 Trade payables 5 782 6 969 Total 11 024 11 682 2.5.14.2 Financial instruments reported at fair value on balance sheet Contingent consideration and other financial liabilities are reported at fair value in the statement of financial position using Level 3 fair value measurements for which the Group developed unobservable inputs: (€‘000) Level I Level II Level III Total Assets Investment in equity securities — — — — Total Assets — — — — Liabilities Contingent consideration and other financial liabilities — — 27 199 27 199 Total Liabilities — — 27 199 27 199 The change in the balance is detailed as follows: As of June 30, As of December 31, (€‘000) 2020 2019 Opening balance Contingent consideration at 1 January 19 853 20 282 Milestone payment — — Fair value adjustment 1 966 (430 ) Currency Translation Adjustment — — Closing balance Contingent consideration at June 30 21 819 19 853 Opening balance Other financial liabilities at 1 January 4 901 4 905 Fair value adjustment 479 (4 ) Closing balance Other financial liabilities at June 30 5 380 4 901 Total - Contingent consideration and Other financial liabilities 27 199 24 754 The contingent consideration and other financial liabilities refer to the acquisition of the Group’s immune-oncology platform and corresponds to the fair value of the risk-adjusted future payments due to Celdara Medical, LLC and Dartmouth College. Its net increase at balance sheet date is mainly due to the update in WACC used for fair value measurement purposes at interim reporting date and time accretion (which reflects reflects the development of the Group’s product candidates using CAR-T The contingent consideration liability captures the commitments further disclosed under note 5.33 from the Group’s 2019 year-end Key assumptions driving the fair value are: i) 14.1% discount rate (WACC) as of June 30, 2020, compared to 14.6% as of December 31, 2019, ii) -25% year-end PoS Phase I Phase I to II Phase II to III Phase III to BLA BLA to Approval Cumulative PoS AML CRC 100% 63% 26% 45% 83% 6,3% Sensitivity analysis: A variance in key assumptions gives rise to a proportionate impact in the contingent liability fair value computation, as detailed in the Group’s year-end

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Disclosure of leases [text block]	2.5.15 Leases Amounts recognized in the consolidated statements of financial position “Property, plant and equipment” comprise owned and leased assets that do not meet the definition of investment property. As of June 30, 2020 As of December 31, 2019 (€‘000) Property, plant and equipment owned (excluding right-of-use 1 306 1 713 Right-of-use 2 925 3 348 Total Tangible assets 4 231 5 061 The statement of financial position shows the following amounts related to the leases for which the Group is a lessee: As of June 30, 2020 (€‘000) Property Vehicles Equipments Group total Opening balance at January 1, 2020 2 411 273 664 3 348 Additions for the period — 71 37 108 Disposals for the period — (3 ) — (3 ) Depreciation charge for the period (202 ) (56 ) (270 ) (528 ) Closing balance at June 30, 2020 2 209 285 431 2 925 Amounts recognized in the consolidated statements of comprehensive loss The consolidated statements of comprehensive loss show the following amounts related to the leases: For the Six-month period ended June 30, (€‘000) 2020 2019 Depreciation charge of right-of-use Property 202 200 Vehicles 56 36 Equipments 270 286 Interest on lease liabilities (including in Financial expenses) 1 131 150 Interest on sublease receivable (including in Financial income) (26 ) (33 ) Variable lease payments not included in the measurement of lease liabilities — — Expenses relating to short-term leases and leases of low-value 98 85 Total expenses related to leases 731 724 1 Interests on leases are presented as operating cash flow. Total cash outflows for leases (€’000) For the Six-month period ended June 30, 2020 2019 Total cash outflow for leases (including short-term leases and leases of low-value 857 826

Related party transactions

Related party transactions	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Related party transactions	2.5.16 Related party transactions The compensation amounts presented below, awarded to the members of the Board of Directors and the Executive Committee of the Group, were recorded as General & Administrative expenses in the period referenced. (€‘000) For the Six-month period ended June 30, 2020 2019 Independent director’s fees 205 169 Share-based payments 192 149 Total compensation to the Board of Directors 397 318 Executive Management fees 771 1 135 Short-term employee benefits 753 581 Share-based payments 583 445 Total compensation to the Executive Committee 2 107 2 161

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Subsequent events	2.5.17 Subsequent events On July 14, 2020, the Company announced that the FDA accepted the IND application for CYAD-211 In July 2020, the Company was awarded €3.3 million in non-dilutive funding in the form of recoverable cash advances by the Walloon Region associated with Company’s lead allogenic CAR T candidate CYAD-101. The regional funding will help support the development of CYAD-101 for the treatment of mCRC, including the launch of the expansion segment of the ongoing alloSHRINK trial. The funding for technological innovation received on behalf of the Walloon Region was approved by Mr. Willy Borsus, Vice President of Wallonia, Minister of Economy, Foreign Trade, Research and Innovation, Digital, Agriculture and Territorial Development. Under the applicable conditions, the recoverable cash advance is reimbursable over the economic life of the projects. Thirty percent of the cash advance is refundable based on a fixed reimbursement schedule of 20 years, while the balance is refunded in the form of royalties, payable over the same period. There is no other subsequent event that occurred between six-month

Basis of preparation and sign_2

Basis of preparation and significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Basis of preparation of half year report	2.5.2.1 Basis of preparation of half year report The interim condensed consolidated financial statements have been prepared in accordance with the IFRS as issued by the IASB and in accordance with the IFRS as issued by the IASB and as adopted for use in the European Union, and with IAS 34, Interim Financial Reporting. They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the annual financial statements for the year ended December 31, 2019. The preparation of the Company’s financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the end of the interim period. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods. The principal risks during the interim period have not materially changed from those mentioned in the 2019 Annual Report and subsequent reports and filings made with the SEC, each of which are available on the Company’s website ( http://www.celyad.com/investors/regulated-information The COVID-19 All statements and information relate to the interim period unless otherwise stated. The interim condensed consolidated financial statements are presented in thousands of Euros and all values are rounded to the nearest thousand (€’000) except when otherwise indicated. Amounts have been rounded off to the nearest thousand and in certain cases, this may result in minor discrepancies in the totals and sub-totals
New standards, interpretations and amendments	2.5.2.2 New standards, interpretations and amendments The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period. None of the new standards, interpretations and amendments, which are effective for periods beginning after January 1, 2020 which have been issued by the IASB and the IFRIC but are not yet effective as per June 30, 2020 and/or not yet adopted by the European Union as per June 30, 2020, are expected to have a material effect on the Group’s future financial statements.
Critical accounting estimates and judgments	2.5.2.3 Critical accounting estimates and judgments The preparation of interim financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that may significantly affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the end of the reporting period. Refer to the disclosure note 5.4 from the Group’s 2019 year-end

Segment reporting (Tables)

Segment reporting (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Schedule of Segment Profit by Operating Segment	Since mid of 2016, the Group is fully focused on the development of its immuno-oncology platform. Therefore, as of June 30, 2020, most of the R&D expenses were incurred in the immuno-oncology segment, in line with prior year. For the Six-month € ‘000 Cardiology Immuno-oncology Corporate Group Total Revenue recognized at a point in time — — — — Revenue recognized over time — — — — Total Revenue — — — — Cost of Sales — — — — Gross Profit — — — — Research & Development expenses (94 ) (12 612 ) — (12 706 ) General & Administrative expenses — — (4 506 ) (4 506 ) Net Other income/(loss) 134 927 201 1 262 Operating Profit/(Loss) 40 (11 685 ) (4 305 ) (15 950 ) Net financial income/(loss) 93 (93 ) (15 ) (15 ) Profit/(Loss) before taxes 133 (11 778 ) (4 320 ) (15 965 ) Income Taxes — — — — Profit/(Loss) for the year 2019 133 (11 778 ) (4 320 ) (15 965 ) For the Six-month € ‘000 Cardiology Immuno-oncology Corporate Group Total Revenue recognized at a point in time 5 — — 5 Revenue recognized over time — — — — Total Revenue 5 — — 5 Cost of Sales — — — — Gross Profit 5 — — 5 Research & Development expenses (72 ) (11 069 ) — (11 141 ) General & Administrative expenses — — (4 789 ) (4 789 ) Net Other income/(loss) 10 (840 ) 200 (630 ) Operating Profit/(Loss) (57 ) (11 908 ) (4 589 ) (16 555 ) Net financial income/(loss) — (87 ) 45 (42 ) Profit/(Loss) before taxes (57 ) (11 995 ) (4 545 ) (16 597 ) Income Taxes — — (0 ) (0 ) Profit/(Loss) for the year 2020 (57 ) (11 995 ) (4 545 ) (16 597 )

Results of Operations (Tables)

Results of Operations (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Summary of Revenues	For the Six-month period ended June 30, (€‘000) 2020 2019 Out-licensing — — Other revenue 5 — Total Revenue 5 —
Summary of Research And Development Expenses	Research and development expenses The following table is a summary of manufacturing expenses, clinical, quality and regulatory expenses and other research and development expenses, which are aggregated and presented as research and development expenses in the Group’s consolidated financial statements. For the Six-month period ended June 30, (€‘000) 2020 2019 Employee expenses 4 528 4 179 Travel & Living 107 198 Clinical study costs 2 720 2 786 Preclinical study costs 866 1 729 Process development and scale-up 803 1 504 Consulting fees 191 574 IP filing and maintenance fees 141 135 Share-based payments 398 515 Depreciation 727 719 Rent and utilities 415 366 Others 245 2 Total R&D expenses 11 141 12 706
Summary of General and Administrative Expenses	General and administrative expenses For the Six-month period ended June 30, (€‘000) 2020 2019 Employee expenses 1 733 1 951 Consulting fees 1 025 865 Share-based payments 892 776 Communication & Marketing 289 339 Rent 40 18 Insurances 476 213 Travel & living 77 166 Depreciation 168 177 Others 89 1 Total General and administrative expenses 4 789 4 506
Summary of Other Income and Expenses	Other income and Other expenses For the Six-month period ended June 30, (€‘000) 2020 2019 Remeasurement of contingent consideration 2 445 — Clinical Development milestone payment 105 — Remeasurement of RCA’s 105 13 Fair value adjustment on securities — — Others 0 36 Total Other Expenses 2 656 49 Grant income (RCA’s) 615 517 Grant income (Other) 1 023 — Remeasurement of RCA’s — — Fair value adjustment on securities — 182 Remeasurement of contingent consideration — 407 R&D tax credit 371 205 Others 16 — Total Other Income 2 026 1 311
Earnings (Loss) Per Share	For the Six-month period ended June 30, (€‘000) 2020 2019 Loss for the period attributable to Equity Holders (16 597 ) (15 965 ) Weighted average number of shares outstanding 13 942 344 11 942 344 Earnings per share (non-fully (1,19 ) (1,34 ) Outstanding warrants 1 594 156 1 292 380

Liquidity and Capital Resourc_2

Liquidity and Capital Resources (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Summary of Consolidated Cash Flows Information	The following table sets forth the Group’s condensed interim consolidated cash flows information for the six-month For the Six-month period ended June 30, (€‘000) 2020 2019 Net cash used in operations (14 633 ) (16 063 ) Net cash (used in)/from investing activities 50 9 090 Net cash (used in)/from financing activities 1 929 97 Effects of exchange rate changes 7 2 Change in Cash and cash equivalents (12 646 ) (6 874 ) Change in Short-term investments — (9 197 ) Net cash burned over the period (12 646 ) (16 071 )

Goodwill and Intangible assets

Goodwill and Intangible assets (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Summary of Goodwill and Intangible Assets	As of June 30, As of December 31, (€‘000) 2020 2019 OnCyte IPRD 33 676 33 676 C-Cath 573 607 Goodwill 883 883 Patents & Licenses 911 964 Other intangible assets 62 69 Total Goodwill and Intangible assets 36 106 36 199

Trade and Other receivables (Ta

Trade and Other receivables (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Summary of Other Non-current Assets	As of June 30, As of December 31, (€‘000) 2020 2019 R&D Tax credit receivable 3 378 3 051 Total Non-current Grant receivables 3 378 3 051 Deposits 231 257 Total Other non-current 231 257
Summary of Detailed Information About Non-current Trade Receivables	As of June 30, As of December 31, (€‘000) 2020 2019 Non-current 2 032 1 955 Net investment in Lease 343 477 Total Non-current 2 375 2 432
Summary of Trade, Other Receivables and Other current assets	As of June 30, As of December 31, (€‘000) 2020 2019 Trade receivables 451 156 Advance deposits 260 149 Net Investment in Lease 261 253 Other receivables — — Total Trade and Other receivables 972 558 Current Grant receivables (RCAs) 272 693 Current Grant receivables (Others) 569 993 Total Current Grant receivables 841 1 686 Prepaid expenses 364 646 VAT receivable 430 356 Income and other tax receivables 140 251 Total Other current assets 934 1 253 Total Trade receivables, advances and other current assets 2 747 3 497

Short-term investments and Ca_2

Short-term investments and Cash and Cash equivalents (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Summary of Short Term Investments and Cash and Cash Equivalents	As of June 30, As of December 31, (€‘000) 2020 2019 Short-term investments — — Cash and cash equivalents 26 692 39 338 Total Short-term investments and Cash and Cash equivalents 26 692 39 338

Capital and share premium (Tabl

Capital and share premium (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Summary of capital and share premium	As of June 30, As of December 31, (€‘000) 2020 2019 Capital 48 513 48 513 Share premium 43 349 43 349 # Outstanding shares 13 942 344 13 942 344

Recoverable Cash Advances (Tabl

Recoverable Cash Advances (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Summary of Current and Non-current Portion Cash Advances	As of June 30, As of December 31, (€‘000) 2020 2019 Non-current 4 538 4 139 Current portion 613 346 Total Recoverable Cash Advances 5 151 4 484

Trade Payables and Other Curr_2

Trade Payables and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Trade Payables and Other Current Liabilities	As of June 30, As of December 31, (€‘000) 2020 2019 Total trade payables 5 782 6 969 Other current liabilities Social security 165 482 Payroll accruals and taxes 1 480 1 750 Other current liabilities 1 563 1 016 Total other current liabilities 3 208 3 248 Total Trade payables and other current liabilities 8 989 10 217

Financial Instruments Fair Va_2

Financial Instruments Fair Value Disclosures (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Summary of Carrying and Fair Values of Financial Instruments that are not Reported at Fair Value	The carrying and fair values of financial instruments that are not reported at fair value in the interim financial statements were as follows for the current and comparative periods: As of June 30, As of December 31, (€‘000) 2020 2019 Financial Assets (‘Amortized cost’ category) within: Non-current 2 375 2 432 Other non-current 231 257 Trade receivables and other current assets 972 558 Short-term investments — — Cash and cash equivalents 26 692 39 338 Total 30 272 42 586 As of June 30, As of December 31, (€‘000) 2020 2019 Financial Liabilities (‘Financial liabilities at amortized cost’ category) within: Bank loans 91 229 RCA’s liability 5 151 4 484 Trade payables 5 782 6 969 Total 11 024 11 682
Schedule of Financial Assets and Liabilities Measured at Fair Value	Contingent consideration and other financial liabilities are reported at fair value in the statement of financial position using Level 3 fair value measurements for which the Group developed unobservable inputs: (€‘000) Level I Level II Level III Total Assets Investment in equity securities — — — — Total Assets — — — — Liabilities Contingent consideration and other financial liabilities — — 27 199 27 199 Total Liabilities — — 27 199 27 199
Contingent Consideration and Other Financial Liabilities	The change in the balance is detailed as follows: As of June 30, As of December 31, (€‘000) 2020 2019 Opening balance Contingent consideration at 1 January 19 853 20 282 Milestone payment — — Fair value adjustment 1 966 (430 ) Currency Translation Adjustment — — Closing balance Contingent consideration at June 30 21 819 19 853 Opening balance Other financial liabilities at 1 January 4 901 4 905 Fair value adjustment 479 (4 ) Closing balance Other financial liabilities at June 30 5 380 4 901 Total - Contingent consideration and Other financial liabilities 27 199 24 754
Sensitivity Analysis Performed on Main Assumptions	Key assumptions driving the fair value are: i) 14.1% discount rate (WACC) as of June 30, 2020, compared to 14.6% as of December 31, 2019, ii) -25% year-end PoS Phase I Phase I to II Phase II to III Phase III to BLA BLA to Approval Cumulative PoS AML CRC 100% 63% 26% 45% 83% 6,3%

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Summary of Property Plant And Equipment Owned And Leased Assets	“Property, plant and equipment” comprise owned and leased assets that do not meet the definition of investment property. As of June 30, 2020 As of December 31, 2019 (€‘000) Property, plant and equipment owned (excluding right-of-use 1 306 1 713 Right-of-use 2 925 3 348 Total Tangible assets 4 231 5 061
Summary of Lease Liabilities	The statement of financial position shows the following amounts related to the leases for which the Group is a lessee: As of June 30, 2020 (€‘000) Property Vehicles Equipments Group total Opening balance at January 1, 2020 2 411 273 664 3 348 Additions for the period — 71 37 108 Disposals for the period — (3 ) — (3 ) Depreciation charge for the period (202 ) (56 ) (270 ) (528 ) Closing balance at June 30, 2020 2 209 285 431 2 925
Summary of Lease Expense	The consolidated statements of comprehensive loss show the following amounts related to the leases: For the Six-month period ended June 30, (€‘000) 2020 2019 Depreciation charge of right-of-use Property 202 200 Vehicles 56 36 Equipments 270 286 Interest on lease liabilities (including in Financial expenses) 1 131 150 Interest on sublease receivable (including in Financial income) (26 ) (33 ) Variable lease payments not included in the measurement of lease liabilities — — Expenses relating to short-term leases and leases of low-value 98 85 Total expenses related to leases 731 724 1 Interests on leases are presented as operating cash flow.
Summary of Cash Outflow For Leases	Total cash outflows for leases (€’000) For the Six-month period ended June 30, 2020 2019 Total cash outflow for leases (including short-term leases and leases of low-value 857 826

Related party transactions (Tab

Related party transactions (Tables)	6 Months Ended
	Jun. 30, 2020
Text block [abstract]
Summary of Compensation to the Members of the Board of Directors and the Executive Management Team	(€‘000) For the Six-month period ended June 30, 2020 2019 Independent director’s fees 205 169 Share-based payments 192 149 Total compensation to the Board of Directors 397 318 Executive Management fees 771 1 135 Short-term employee benefits 753 581 Share-based payments 583 445 Total compensation to the Executive Committee 2 107 2 161

General Information - Additiona

General Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2020Subsidiaries
Disclosure of detailed information about business combination [abstract]
Number of subsidiaries owned by the entity	3

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015Segment
Disclosure of operating segments [line items]
Number of operating segments	2

Segment Reporting - Schedule of

Segment Reporting - Schedule of Segment Profit by Operating Segment (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Disclosure of operating segments [line items]
Revenue recognized at a point in time	€ 5
Revenue recognized over time
Total Revenue	5
Cost of sales
Gross profit	5
Research and Development expenses	(11,141)		(12,706)
General & Administrative expenses	(4,789)		(4,506)
Net Other income/(loss)	(630)		1,262
Operating Loss	(16,555)		(15,950)
Net Financial income/(loss)	(42)		(15)
Loss before taxes	(16,597)		(15,965)
Income Taxes	0
Profit/(Loss) for the year	(16,597)	€ (12,667)	(15,965)
Cardiology [member]
Disclosure of operating segments [line items]
Revenue recognized at a point in time	5
Total Revenue	5
Gross profit	5
Research and Development expenses	(72)		(94)
Net Other income/(loss)	10		134
Operating Loss	(57)		40
Net Financial income/(loss)			93
Loss before taxes	(57)		133
Profit/(Loss) for the year	(57)		133
Immuno-oncology [member]
Disclosure of operating segments [line items]
Research and Development expenses	(11,069)		(12,612)
Net Other income/(loss)	(840)		927
Operating Loss	(11,908)		(11,685)
Net Financial income/(loss)	(87)		(93)
Loss before taxes	(11,995)		(11,778)
Profit/(Loss) for the year	(11,995)		(11,778)
Corporate [member]
Disclosure of operating segments [line items]
General & Administrative expenses	(4,789)		(4,506)
Net Other income/(loss)	200		201
Operating Loss	(4,589)		(4,305)
Net Financial income/(loss)	45		(15)
Loss before taxes	(4,545)		(4,320)
Income Taxes	0
Profit/(Loss) for the year	€ (4,545)		€ (4,320)

Off-Balance Sheet Commitments -

Off-Balance Sheet Commitments - Additional Information (Detail) € in Thousands	Jun. 30, 2020EUR (€)
Off Balance Sheet Commitments [Abstract]
Off-balance sheet commitments	€ 0

Results of Operations - Additio

Results of Operations - Additional Information (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Disclosure of reporting entity [line items]
Total R&D expenses	€ 11,141		€ 12,706
Research and development expense increase percentage	12.00%
Total general and administrative expenses	€ 300
Clinical Development Milestone Payments	105
Operating loss	(16,555)		(15,950)
Increase in operating loss	600
Interest expense on finance leases	131		150
Increase in loss for the period	600
Loss for the period	(16,597)	€ (12,667)	(15,965)
Change in value of interest income bank account	200
Other income	2,026		1,311
Research and Development [Member]
Disclosure of reporting entity [line items]
Other income	400
Finance Leases [Member]
Disclosure of reporting entity [line items]
Interest expense on finance leases	100
Federal Belgian Institute For Health Insurance Inami [Member]
Disclosure of reporting entity [line items]
Grant income recoverable cash advances received	200
Regional Government [Member]
Disclosure of reporting entity [line items]
Grant income recoverable cash advances received	800
Contingent consideration and other financial liabilities [member]
Disclosure of reporting entity [line items]
Income on fair value adjustment	2,400
Expense on fair value adjustment			€ 400
Walloon Region [Member]
Disclosure of reporting entity [line items]
Grant income recoverable cash advances received	1,400
Contracted recoverable cash advances	600
Liability component of the cash settlement	€ 800

Results of Operations - Summary

Results of Operations - Summary of Revenues (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Disclosure of disaggregation of revenue from contracts with customers [abstract]
Out-licensing revenue	€ 0
Other revenue	5
Total Revenue	€ 5

Results of Operations - Summa_2

Results of Operations - Summary of Research and Development Expenses (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Research And Development Expenses [Abstract]
Employee expenses	€ 4,528	€ 4,179
Travel & Living	107	198
Clinical study costs	2,720	2,786
Preclinical study costs	866	1,729
Process development and scale-up	803	1,504
Consulting fees	191	574
IP filing and maintenance fees	141	135
Share-based payments	398	515
Depreciation	727	719
Rent and utilities	415	366
Others	245	2
Total R&D expenses	€ 11,141	€ 12,706

Results of Operations - Summa_3

Results of Operations - Summary of General and Administrative Expenses (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Other General And Administrative Expenses [abstract]
Employee expenses	€ 1,733	€ 1,951
Consulting fees	1,025	865
Share-based payments	892	776
Communication & Marketing	289	339
Rent	40	18
Insurances	476	213
Travel & living	77	166
Depreciation	168	177
Other	89	1
Total General and administrative expenses	€ 4,789	€ 4,506

Results of Operations - Summa_4

Results of Operations - Summary of Other Income and Expenses (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Disclosure of disaggregation of revenue from contracts with customers [abstract]
Remeasurement of contingent consideration	€ 2,445
Clinical Development milestone payment	105
Remeasurement of RCA's	105	€ 13
Fair value adjustment on securities	0
Others	0	36
Total Other Expenses	2,656	49
Grant income (RCA's)	615	517
Grant income (Other)	1,023
Remeasurement of RCA's	0
Fair value adjustment on securities		182
Remeasurement of contingent consideration		407
R&D tax credit	371	205
Others	16
Total Other Income	€ 2,026	€ 1,311

Results of Operations - Calcula

Results of Operations - Calculation of Earnings (Loss) Per Share (Detail) - EUR (€) € / shares in Units, € in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Earnings per share [abstract]
Loss for the period attributable to Equity Holders	€ (16,597)	€ (12,667)	€ (15,965)
Weighted average number of shares outstanding	13,942,344		11,942,344
Earnings per share (non-fully diluted) in €	€ (1.19)		€ (1.34)
Outstanding warrants	1,594,156		1,292,380

Liquidity and capital resourc_3

Liquidity and capital resources - Additional Information (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure Of Regulatory Capital Resources [Line Items]
Private investment fund	€ 67,000
Public investment fund	230,000
Investment fund	297,000
Financial liabilities	27,199
Pending contract	11,600
Cash outflow from operations	(14,633)	€ (16,063)
Cash flow from investing activities	50	9,090
Cash flow from financing activities	1,929	97
Federal Belgian Institute For Health Insurance Inami [Member]
Disclosure Of Regulatory Capital Resources [Line Items]
Additional grants received			€ 400
Regional Government [Member]
Disclosure Of Regulatory Capital Resources [Line Items]
Additional grants received	2,400
RCA's [member]
Disclosure Of Regulatory Capital Resources [Line Items]
Financial liabilities	5,200
Increase decrease in cash flow from financing activities		1,400
Other Grants [Member]
Disclosure Of Regulatory Capital Resources [Line Items]
Increase decrease in cash flow from financing activities		1,300
Walloon Region [Member]
Disclosure Of Regulatory Capital Resources [Line Items]
Additional grants received	1,900
Cash flow from financing activities	2,700	1,100
Cash inflow	1,800
Amount received	6,100
Celdara Medical [member]
Disclosure Of Regulatory Capital Resources [Line Items]
Financial liabilities	27,200
AML and MDS franchise [Member]
Disclosure Of Regulatory Capital Resources [Line Items]
Cash outflow from operations	(14,600)	€ (16,100)
Decrease in cash outflow from operations	1,400
Short Term Investments [Member]
Disclosure Of Regulatory Capital Resources [Line Items]
Increase in cash outflow from investing activities	€ (9,000)

Liquidity and capital resourc_4

Liquidity and capital resources - Summary of Consolidated Cash Flows Information (Detail) - EUR (€) € in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Cash Flows From Capital Increase [Abstract]
Net cash used in operations	€ (14,633)	€ (16,063)
Net cash (used in)/from investing activities	50	9,090
Net cash (used in)/from financing activities	1,929	97
Effects of exchange rate changes	7	2
Change in Cash and cash equivalents	(12,653)	(6,876)
Change in Short-term investments		(9,197)
Net cash burned over the period	€ (12,646)	€ (16,071)	€ 12,600

Goodwill and Intangible asset_2

Goodwill and Intangible assets - Summary of Goodwill and Intangible Assets (Detail) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Disclosure of detailed information about intangible assets [line items]
Goodwill and Intangible assets	€ 36,106	€ 36,199
On Cyte IPRD [member]
Disclosure of detailed information about intangible assets [line items]
Goodwill and Intangible assets	33,676	33,676
C-Cath Development Costs [member]
Disclosure of detailed information about intangible assets [line items]
Goodwill and Intangible assets	573	607
Goodwill [member]
Disclosure of detailed information about intangible assets [line items]
Goodwill and Intangible assets	883	883
Patents and Licences [Member]
Disclosure of detailed information about intangible assets [line items]
Goodwill and Intangible assets	911	964
Other intangible assets [member]
Disclosure of detailed information about intangible assets [line items]
Goodwill and Intangible assets	€ 62	€ 69

Goodwill and Intangible asset_3

Goodwill and Intangible assets - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2020EUR (€)
Disclosure of detailed information about intangible assets [line items]
Impairment of intangible assets	€ 0

Trade and Other receivables - S

Trade and Other receivables - Summary of Non-current Financial Assets (Detail) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Disclosure of Other Noncurrent Assets [abstract]
R&D Tax credit receivable	€ 3,378	€ 3,051
Total Non-current Grant receivables	3,378	3,051
Deposits	231	257
Total Other non-current assets	€ 231	€ 257

Trade and Other receivables -_2

Trade and Other receivables - Summary of Detailed Information About Non-current Trade Receivables (Detail) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Disclosure of other non current assets [line items]
Non-current trade receivables Mesoblast licence agreement	€ 2,375	€ 2,432
Net investment in Lease	343	477
Mesoblast licence agreement [member]
Disclosure of other non current assets [line items]
Non-current trade receivables Mesoblast licence agreement	€ 2,032	€ 1,955

Trade and Other receivables -_3

Trade and Other receivables - Summary of Trade Receivables and Other Current Assets (Detail) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Disclosure of trade and other receivables [abstract]
Trade receivables	€ 451	€ 156
Advance deposits	260	149
Net Investment in Lease	261	253
Total Trade and Other receivables	972	558
Current Grant receivables (RCAs)	272	693
Current Grant receivables (Others)	569	993
Total Current Grant receivables	841	1,686
Prepaid expenses	364	646
VAT receivable	430	356
Income and other tax receivables	140	251
Total Other current assets	934	1,253
Total Trade receivables, advances and other current assets	€ 2,747	€ 3,497

Trade and Other receivables - A

Trade and Other receivables - Additional Information (Detail) € in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)
Disclosure of trade and other receivables [line items]
Increase in trade receivables	€ 0.4
Decrease in other current asset	0.3
Walloon Region [Member]
Disclosure of trade and other receivables [line items]
Grant receivables due to related parties	€ 0.8

Short-term investments and Ca_3

Short-term investments and Cash and Cash equivalents - Summary of Short Term Investments and Cash and Cash Equivalents (Detail) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Short term investments1 [abstract]
Short-term investments	€ 0	€ 0
Cash and cash equivalents	26,692	39,338	€ 33,668	€ 40,542
Total Short-term investments and Cash and Cash equivalents	€ 26,692	€ 39,338

Short-term investments and Ca_4

Short-term investments and Cash and Cash equivalents - Additional Information (Detail) - EUR (€) € in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Short term investments1 [abstract]
Treasury position	€ 26,700
Cash burned	€ (12,646)	€ (16,071)	€ 12,600

Capital and share premium - Sum

Capital and share premium - Summary of capital and share premium (Detail) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Disclosure of classes of share capital [abstract]
Capital	€ 48,513	€ 48,513
Share premium	€ 43,349	€ 43,349
Outstanding shares	13,942,344	13,942,344

Capital and share premium - Add

Capital and share premium - Additional Information (Detail) - EUR (€) € / shares in Units, € in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Disclosure of classes of share capital [abstract]
Share Capital	€ 48,513	€ 48,513
Number of ordinary shares	13,942,344
Common stock , par value	€ 0
Increase in capital	€ 0

Recoverable Cash Advances - Sum

Recoverable Cash Advances - Summary of Current and Non-current Portion Cash Advances (Detail) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Disclosure of financial liabilities [abstract]
Non-current portion	€ 4,538	€ 4,139
Current portion	613	346
Total Recoverable Cash Advances	€ 5,151	€ 4,484

Recoverable Cash Advances - Add

Recoverable Cash Advances - Additional Information (Detail) € in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)
Disclosure of financial liabilities [line items]
Net increase in recoverable cash advances	€ 0.7
Walloon Region [member]
Disclosure of financial liabilities [line items]
Cash settlement liability paid	0.8
Cash settlement	€ 1.4

Trade Payables and Other Curr_3

Trade Payables and Other Current Liabilities - Trade Payables and Other Current Liabilities (Detail) - EUR (€) € in Thousands	Jun. 30, 2020	Dec. 31, 2019
Trade and other current payables [abstract]
Total trade payables	€ 5,782	€ 6,969
Other current liabilities
Social security	165	482
Payroll accruals and taxes	1,480	1,750
Other current liabilities	1,563	1,016
Total other current liabilities	3,208	3,248
Total Trade payables and other current liabilities	€ 8,989	€ 10,217

Trade Payables and Other Curr_4

Trade Payables and Other Current Liabilities - Additional Information (Detail) € in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Decrease in trade payable	€ 1.2
Decrease on social security, payroll accruals and taxes	0.6
Increase in other current liabilities	0.5
Reimbursement of R&D tax credit	1
Federal Belgian Institute for Health Insurance Inami [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Recognition of deferred revenue	€ 0.2

Financial Instruments Fair Va_3

Financial Instruments Fair Value Disclosures - Summary of Carrying and Fair Values of Financial Instruments that are not Reported at Fair Value (Detail) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Financial Assets
Non-current trade receivables	€ 2,375	€ 2,432
Other non-current assets	231	257
Trade receivables and other current assets		558
Short-term investments		0
Cash and cash equivalents	26,692	39,338	€ 33,668	€ 40,542
At fair value [member]
Financial Assets
Non-current trade receivables	2,375	2,432
Other non-current assets	231	257
Trade receivables and other current assets	972
Short-term investments	0	0
Cash and cash equivalents	26,692	39,338
Total	30,272	42,586
Financial Liabilities
Bank loans	91	229
RCA's liability	5,151	4,484
Trade payables	5,782	6,969
Total	€ 11,024	€ 11,682

Financial Instruments Fair Va_4

Financial Instruments Fair Value Disclosures - Schedule of Financial Assets and Liabilities Measured at Fair Value (Detail) € in Thousands	Jun. 30, 2020EUR (€)
Disclosure of detailed information about financial instruments [line items]
Investment in equity securities	€ 0
Financial assets, at fair value	0
Financial liabilities, at fair value	27,199
Contingent consideration and other financial liabilities [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, at fair value	27,199
Level I [member]
Disclosure of detailed information about financial instruments [line items]
Investment in equity securities	0
Financial assets, at fair value	0
Level II [member]
Disclosure of detailed information about financial instruments [line items]
Investment in equity securities	0
Financial assets, at fair value	0
Level III [member]
Disclosure of detailed information about financial instruments [line items]
Investment in equity securities	0
Financial assets, at fair value	0
Financial liabilities, at fair value	27,199
Level III [member] | Contingent consideration and other financial liabilities [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, at fair value	€ 27,199

Financial Instruments Fair Va_5

Financial Instruments Fair Value Disclosures - Summary of Contingent Consideration and Other Financial Liabilities (Detail) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]
Total - Contingent consideration and Other financial liabilities	€ 27,199	€ 24,754
Contingent consideration [member]
Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]
Opening balance Contingent consideration at 1 January	19,853	20,282
Fair value adjustment	1,966	(430)
Closing balance Contingent consideration at June 30	21,819	19,853
Opening balance Other financial liabilities at 1 January	4,901	4,905
Fair value adjustment	479	(4)
Closing balance Other financial liabilities at June 30	5,380	4,901
Total - Contingent consideration and Other financial liabilities	€ 27,199	€ 24,754

Financial Instruments Fair Va_6

Financial Instruments Fair Value Disclosures - Additional Information (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Disclosure of detailed information about financial instruments [abstract]
Weighted average cost of capital discount rate	14.10%	14.60%
Decrease in long term sales growth rate	25.00%	25.00%

Financial Instruments Fair Va_7

Financial Instruments Fair Value Disclosures - Schedule of Sensitivity Analysis Performed on Main Assumptions (Detail)	6 Months Ended
	Jun. 30, 2020
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Probablity of success percentage	63.00%
Phase I [member]
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Probablity of success percentage	100.00%
Phase I to II [member]
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Probablity of success percentage	63.00%
Phase II to III [member]
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Probablity of success percentage	26.00%
Phase III to BLA [member]
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Probablity of success percentage	45.00%
BLA to approval [member]
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Probablity of success percentage	83.00%

Leases - Summary of Property Pl

Leases - Summary of Property Plant and Equipment Owned and Leased Assets (Detail) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Disclosure Of Leases [Abstract]
Property, Plant and Equipment owned (excluding right-of-use assets)	€ 1,306	€ 1,713
Right-of-use assets	2,925	3,348
Total Tangible assets	€ 4,231	€ 5,061

Leases - Summary of Rights to U

Leases - Summary of Rights to Use Assets (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance	€ 3,348
Additions for the period	108
Disposals for the period	(3)
Depreciation charge for the period	(528)
Closing balance	2,925
Property [member]
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance	2,411
Depreciation charge for the period	(202)
Closing balance	2,209
Vehicles [member]
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance	273
Additions for the period	71
Disposals for the period	(3)
Depreciation charge for the period	(56)	€ (36)
Closing balance	285
Plant and Equipments [member]
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance	664
Additions for the period	37
Depreciation charge for the period	(270)	€ (286)
Closing balance	€ 431

Leases - Summary of lease expen

Leases - Summary of lease expense (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Depreciation charge of right-of-use assets
Depreciation, right-of-use assets	€ 528
Interest on lease liabilities (including in Financial expenses)	131	€ 150
Interest on sublease receivable (including in Financial income)	(26)	(33)
Expenses relating to short-term leases and leases of low-value assets	98	85
Total expenses related to leases	731	724
Property Member [Member]
Depreciation charge of right-of-use assets
Depreciation, right-of-use assets	202	200
Vehicles [member]
Depreciation charge of right-of-use assets
Depreciation, right-of-use assets	56	36
Plant and Equipments [Member]
Depreciation charge of right-of-use assets
Depreciation, right-of-use assets	€ 270	€ 286

Leases - Summary of Cash Outflo

Leases - Summary of Cash Outflow For Leases (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Disclosure of quantitative information about right-of-use assets [line items]
Total cash outflow for leases (including short-term leases and leases of low-value assets)	€ 857	€ 826

Related party transactions - Su

Related party transactions - Summary of Compensation to the Members of the Board of Directors and the Executive Management Team (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Board of director [member]
Disclosure of compensation of key management personnel [line items]
Independent director's fees	€ 205	€ 169
Share-based payments	192	149
Total compensation	397	318
Executive management [member]
Disclosure of compensation of key management personnel [line items]
Executive Management fees	771	1,135
Short-term employee benefits	753	581
Share-based payments	583	445
Total compensation	€ 2,107	€ 2,161

Subsequent events - Additional

Subsequent events - Additional Information (Detail) - EUR (€) € in Thousands	1 Months Ended	6 Months Ended
	Jul. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from RCAs & other grants		€ 2,695	€ 1,086
Major Recoverable Cash Advances Transaction [Member]
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from RCAs & other grants	€ 3,300
Recoverable Cash Advances, Repayment Term	20 years
Repayable recoverable cash advances percentage	30.00%